1 17 1

Additional Partnered Programs

In addition to its proprietary product pipeline, MacroGenics has several fully-partnered DART-based product candidates through the following strategic collaborations: (more info)


September 2014


January 2013


October 2010


October 2010
Home»Pipeline

Product Pipeline

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future.  Set forth below is the company's development pipeline of product candidates for which we have retained commercialization rights in the U.S. or more broadly.

 

Program (Target) Indication Partner Pre-Clin. Phase 1 Phase 2 Phase 3
ONCOLOGY        
Margetuximab * (HER2) Gastroesophageal *  *  *  * 
Metastatic Breast *  *  *  * 
Solid Tumors *  *  *  * 
MGA271 ** (B7-H3) Solid Tumors *  *  *  * 
MGD006 ** (CD123 x CD3) AML *  *  *  * 
MGD007 ** (gpA33 x CD3) Colorectal *  *  *  * 
Multiple DARTs   Various *  *  *  * 
AUTOIMMUNE        
Teplizumab  (CD3) T1D - At-Risk (NIH) *  *  *  * 
MGD010 *** (CD32B x CD79B) Lupus, RA *  *  *  * 
DART ****  Autoimmune *  *  *  * 

*Green Cross has marketing rights in Korea only.

**MacroGenics retains rights in U.S., Canada, Mexico, Japan, Korea & India.

***MacroGenics retains option to co-promote in U.S. and may fund portion of Phase 3 in exchange for North American profit share.

****MacroGenics retains option to co-promote certain products in U.S.

Major Rights Retained
Partnered Globally